EXELIXIS INC. news, videos and press releases
For more news please use our advanced search feature.
EXELIXIS INC. - More news...
EXELIXIS INC. - More news...
- Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
- Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
- Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
- Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
- Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
- Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
- Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
- Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
- Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
- Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
- Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
- Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
- Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
- Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
- Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
- Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
- Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
- Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
- Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
- Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
- Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
- Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
- Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
- Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
- Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
- Exelixis Advances Board Refreshment Plan
